Parathyroid hormone: The clinical experience and prospects

Anabolic Treatments for Osteoporosis

Volumn , Issue , 2013, Pages 83-108

  Hodsman, A B ^a   Fraher, L J ^a   Watson, P H ^a  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055202252     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (67)

1. Reeve, J., Hesp, R., Williams, D., Klenerman, L., Zanelli, J. M., Darby, A. J., Tregear, G. W., Parsons, J. A., and Hume, R., Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet, 1, 1035, 1976.
2. Reeve, J., Tregear, G. W., and Parsons, J. A., Preliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis, Clin. Endocrinol., 21, 469, 1976.
3. Reeve, J., Meunier, P. J., Parsons, J. A., Bernat, M., Bijvoet, O. L. M., Courpron, P., Edouard, C., Lenerman, L., Neer, R. M., Renier, J. C., Slovik, D., Vismans, F. J. F. E., and Potts, J. T. J., Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial, Br. Med. J., 1340, 1980.
4. Finkelstein, J. S., Klibanski, A., Schaefer, e. H., Hornstein, M. D., Schiff, I., and Neer, R. M., Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency, N. Engl. J. Med., 331, 1618, 1994.
5. Reeve, J. Arlot, M., Price, T. R., Edouard, C., Hesp, R., Hulme, P., Ashley, J. P., Zanelli, J. M., Green, J. R., Tellez, M., Katz, D., Spinks, T. J., and Meunier, P. J., Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis: Eur. J. Clin. Invest., 17, 421, 1987.
6. Hesch, R. D., Busch, U., Prokop, M., Delling, G., and Rittinghaus, E. F., Increase of vertebral density by combination therapy with pulsatile 1-38 hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients, Calif. Tissue Int., 44, 176, 1989.
7. Hodsman, A. B. and Fraher, L. J., Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients, Bone Miner., 9, 137, 1990.
8. Hodsman, A. B., Steer, B. M., Fraher, L. J., and Drost, D. J., Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients, Bone Miner., 14, 67, 1991.
9. Hodsman, A. B., Fraher, L. J., Ostbye, T., Adachi, J. D., and Steer, B. M., An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis, J. Clin. Invest., 91, 1138, 1993.
10. Hodsman, A. B., Fraher, L. J., Watson, P. H., Ostbye, T., Stitt, L. W., Adachi, J. D., Taves, D. H., and Drost, D., A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in post-menopausal women with osteoporosis, J. Clin. Endocrinol. Metab., 82, 620, 1997.
11. Fraher, L., Hodsman, A. B., Jonas, K., Saunders, D., Rose, C. I., Henderson, J. E., Hendy, G. N., and Goltzman, D. A., Comparison of the in vivo biochemical responses to exogenous parathyroid hormone (1-34) and parathyroid hormone-related peptide (1-34) in man, J. Clin. Endocrinol. Metab., 75, 417, 1992.
12. Riggs, B. L., Hodgson, S. F., O’Fallon, W. M., Chao, E. Y. S., Wahner, H. W., Muhs, J. M., Cedel, S. L., and Melton, L. III, Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis, N. Engl. J. Med., 322, 802, 1990.
13. Lindsay, R. and Cosman, F., Estrogen in prevention and treatment of osteoporosis, Ann. NY Acad. Sci., 592, 326, 1990.
14. Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Cauley, J., Ensrud, K., Genant, H. K., Palermo, L., Scott, J., and Vogt, T. M., Bone density at various sites for prediction of hip fractures, Lancet, 341, 72, 1993.
15. Ross, P. D., Davis, J. W., Epstein, R. S., and Wasnich, R. D., Pre-existing fracture and bone mass predict vertebral fracture incidence in women, Ann. Int. Med., 114, 919, 1991.
16. Lufkin, E. G., Wahner, H. W., O’Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., and Riggs, B. L., Treatment of postmenopausal osteoporosis with transdermal estrogen, Ann. Int. Med., 117, 1, 1992.
17. Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., and Sorensen, O. H., Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis, N. Engl. J. Med., 322, 1265, 1990.
18. Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C. III, Yanover, J. M., Mysiw, W. J., Kohse, L., Rao, M. B., Steiger, P., and Richmond, B., Intermittent cyclical etidronate treatment of postmenopausal osteoporosis, N. Engl. J. Med., 323, 73, 1990.
19. Liberman, U. A., Weiss, S. R., Broll, J. Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequiker, J., Favus, M., Seeman, E., Recker, R. R., Capizzi, T., Santora, A. C., and Lombardi, A., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, N. Engl. J. Med., 333, 1437, 1995.
20. Pak, C. Y. C., Sakhaee, K., Adams-Huet, B., Piziak, V., Peterson, R. D., and Poindexter, J. R., Treatment of postmenopausal osteoporosis with slow-release sodium fluoride -Final report of a randomized control group, Ann. Int. Med., 123, 401, 1995.
21. Riggs, B. L., O’Fallon, W. M., Lane, A., Hodgson, S. F., Wahner, H. W., Muhs, J., Chao, E., and Melton, L. J., Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis, J. Bone Min. Res., 9, 265, 1994.
22. Slovik, D. M., Rosenthal, D. I., Doppelt, S., Potts, J. T. J., Daly, M. A., Campbell, J. A., and Neer, R. M., Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D, J. Bone Min. Res., 1, 377, 1986.
23. Reeve, J., Davies, U. M., Hesp, R., McNally, E., and Katz, D., Treatment of osteoporosis with human parathyroid peptide and observations on the effect of sodium fluoride, Br. Med. J., 301, 314, 1990.
24. Lindsay, R., Cosman, F., Nieves, J., Dempster, D. W., and Shen, V. A., Controlled clinical trial of the effects of 1-34hPTH in estrogen treated osteoporotic women, J. Bone Min. Res., 8, S130, 1995.
25. Neer, R., Slovik, D., Daly, M., Lo, C., Potts, J., and Nussbaum, S., Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol, in Osteoporosis. Christiansen, C. and Overgaard, K., Eds., Osteopress APS, Copenhagen, 1991.
26. Black, D. M., Bauer, D. C., and Lu, Y., Should BMD be measured at multiple sites to predict fractures in elderly women? J. Bone Min. Res., 10, S140, 1995.
27. Sebert, J. L., Richard, P., Mennencier, I., Bisset, J. P., and Loeb, G., Monofluorophosphate increases lumbar bone density in osteopenic patients: A double-masked randomized study, Osteoporosis Int., 5, 108, 1995.
28. Reginster, J. Y., Deroisy, R., Lecard, M. P., Sarlet, N., Zegels, B., Jupsin, I., De Longueville, M., and Franchimont, P., A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss, Am. J. Med., 98, 452, 1995.
29. Hesp, R., Hulme, P., Williams, D., and Reeve, J., The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1-34), Metab. Bone Dis. Rel. Res., 2, 331, 1981.
30. Slovik, D. M., Neer, R. M., and Potts, J. T. J., Short-term effects of synthetic human parathyroid hormone-(1-34) administration on bone mineral metabolism in osteoporotic patients, J. Clin. Invest., 68, 1261, 1981.
31. Hodsman, A. B. and Drost, D. J., The response of vertebral bone mineral density during the treatment of osteoporosis with sodium fluoride, J. Clin. Endocrinol. Metab., 69, 1, 1989.
32. Reeve, J., Arlot, M. E., Bradbeer, J. N., Hesp, R., Mcally, E., Meunier, P. J., and Zanelli, J. M., Human parathyroid peptide treatment of vertebral osteoporosis, Osteoporosis Int., 3, S199, 1993.
33. Lindsay, R., Cosman, F., Nieves, J., Dempster, D. W., and Shen, V. A., Controlled clinical trial of the effects of 1-34hPTH in estrogen treated osteoporotic women, [Abstract], J. Bone Min. Res., 9, S130, 1993.
34. Bradbeer, J. N., Arlot, M. E., Meunier, P. J., and Reeve, J., Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone, Clin. Endocrinol., 37, 282, 1992.
35. Reeve, J., Bradbeer, J. N., Arlot, M., Davies, U. M., Green, J. R., Hampton, L., Edouard, C., Hesp, R., Hulme, P., Ashby, J. P., Zanelli, J. M., and Meunier, P. J., hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses, Osteoporosis Int., 1, 162, 1991.
36. Chavassieux, P. M., Arlot, M. E., and Meunier, P. J., Intersample variation in bone histomorphometry: comparison between parameter values measured on two contiguous transilica bone biopsies, Calcif. Tissue Int., 37, 345, 1985.
37. Tsai, K.-S., Ebeling, P. R., and Riggs, B. L., Bone responsiveness to parathyroid hormone in normal and osteoporotic postmenopausal women, J. Clin. Endocrinol. Metab., 69, 1024, 1989.
38. Lindsay, R., Nieves, J., Henneman, E., Shen, V., and Cosman, F., Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response to estrogenized osteoporotic patients, J. Clin. Endocrinol. Metab., 77, 1535, 1993.
39. Audran, M., Basle, M. F., Defontaine, A., Jallet, P., Bidet, M. T., Ermias, A., Tanguy, G., Pouplard, A., Reeve, J., Zanelli, J., and Renier, J. C., Transient hypoparathyroidism induced by synthetic human parathyroid hormone-(1-34)-treatment, J. Clin. Endocrinol. Metab., 64, 937, 1987.
40. Hesch, R. D., Busch, U., Prokop, M., Delling, G., Harms, H., and Rittinghaus, E. F., Increase in bone mass and turnover in low turnover osteoporosis by combined (1-38) hPTH and Calcitonin nasal spray, in Calcitonin 88: New Therapeutic Perspectives; the Nasal Spray, Mazzuoli, G. F., Ed., Sandos AG, Basel, 1989, 139.
41. Prank, K., Nowlan, S. J., Harms, H. M., Koppstech, M., Brabant, G., and Hesch, R., Time series prediction of plasma hormone concentration, J. Clin. Invest., 95, 2910, 1995.
42. Delmas, P. D., Schlemmer, A., Gineyts, E., Riis, B., and Christiansen, C., Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis, J. Bone Min. Res., 6, 639, 1991.
43. Riis, B. J., Overgaard, K., and Christiansen, C., Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy, Osteoporosis Int., 5, 276, 1995.
44. Garnero, P., Shih, W. J., Gineyts, E., Karpf, D. B., and Delmas, P. D., Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment, J. Clin. Endocrinol. Metab., 79, 1693, 1994.
45. Hodsman, A. B. and Drost, D. J., The response of vertebral bone mineral density during the treatment of osteoporosis with sodium fluoride, J. Clin. Endocrinol. Metab., 69, 932, 1989.
46. Reeve, J., Arlot, M., Bernat, M., Charhon, S., Edouard, C., Slovik, D., Vismans, F. J. F. E., and Meunier, P. J., Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: the influence of human parathyroid (hPTH 1-34) therapy, Metab. Bone Dis. Rel. Res., 3, 23, 1981.
47. Reeve, J., Arlot, M., Bernat, M., Edouard, C., Hesp, R., Slovik, D., Vismans, F. J. F. E., and Meunier, P. J., Treatment of osteoporosis with human parathyroid fragment 1-34: a positive final tissue balance in trabecular bone, Metab. Bone Dis. Rel. Res., 2, 355, 1980.
48. Neer, R. M., Slovik, D., Doppelt, S., Daly, M., Rosenthal, D., Lo, C., and Potts, J., The use of parathyroid hormone plus 1,25-dihydroxyvitamin D to increase trabecular bone in osteoporotic men and postmenopausal women, in Osteoporosis 1987, Christiansen, C., Johansen, J. S., and Riis, B. J., Eds., Osteopress Aps, Copenhagen, Denmark, 1987, 929.
49. Cosman, F., Shen, V., Xie, F., Seibel, M., Ratcliffe, A., and Lindsay, R., Estrogen protection against bone resorbing effects of parathyroid hormone infusion, Ann. Intern. Med., 118, 337, 1993.
50. Ebeling, P. R., Jones, J. D., Burritt, M. F., Duerson, C. R., Lane, A. W., Hassager, C., Kumar, R., and Riggs, B. L., Skeletal responsiveness to endogenous parathyroid hormone in postmenopausal osteoporosis, J. Clin. Endocrinol. Metab., 75, 1033, 1992.
51. Marcus, R., Villa, M. L., Cheema, M., Cheema, C., Newhall, K., and Holloway, L., Effects of conjugated estrogen on the calcitriol response to parathyroid hormone in postmenopausal women, J. Clin. Endocrinol. Metab., 74, 413, 1992.
52. Lindsay, R., Cosman, F., Shen, V., Nieves, J., and Dempster, D. W., Bone mass increments induced by PTH treatment can be maintained by estrogen, [Abstract], J. Bone Min. Res., 10, S200, 1995.
53. Kent, G. N., Loveridge, N., Reeve, J., and Zanelli, J. M., Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay, Clin. Sci., 68, 171, 1985.
54. Fraher, L. J., Klein, K., Marier, R., Freeman, D., Hendy, G. N., Goltzman, D., and Hodsman, A. B., Comparison of the pharmacokinetics of parenteral parathyroid hormone (1-34) {PTH-(1-34)} and PTH-related peptide (1-34) in healthy young humans, J. Clin. Endocrinol. Metab., 80, 60, 1995.
55. Fraher, L. J., Hodsman, A. B., Steer, B. M., and Freeman, A. A., Comparison of the pharmacokinetics of subcutaneous parathyroid hormone in healthy young and elderly osteoporotic subjects, [Abstract], J. Bone Min. Res., 8, S253, 1993.
56. Hesch, R. D., Heck, J., and Auf’mkolk, B., First clinical observations with hPTH (1-38), a more potent human parathyroid hormone peptide, Horm. Metab. Res., 16, 559, 1984.
57. Whitfield, J. F., Morley, P., Ross, V., Preston, E., Soska, M., Barbier, J.-R., Isaacs, R. J., Maclean, S., Ohannessian-Barry, L., and Willick, G. E., The hypotensive actions of osteogenic and non-osteogenic parathyroid hormone (PTH) fragments, Calif. Tissue Int., 60, 302, 1997.
58. Yee, J. P., Monroe, S. E., and Thiene, K., The effects of RS-66271, a novel hPTHrP(1-34) analog, on serum and urinary markers of PTH-like activity in healthy postmenopausal women, J. Bone Min. Res., 11, S254, 1996.
59. Yee, J. P., Friday, K. J., Monroe, S. E., Fine, G. D., and Thiene, K. A., Double-blind, controlled, crossover study on the effects of subcutaneous injections of RS-66271, a novel analog of hPTHrP(1-34), on blood pressure in postmenopausal women, J. Bone Min. Res., 11, S454, 1996.
60. Henry, J. G., Mitnick, M. A., and Stewart, A. F., Subcutaneous administration of PTHrP(1-36) to humans: a dose-finding study, J. Bone Min. Res., 11, S453, 1996.
61. Deftos, L. J., Nolan, J. J., Seely, B. L., Clopton, P. C., Cote, G. J., Witham, c. L., Florek, L. J., and Christenson, T. A., Intrapulmonary drug delivery of bone-active peptides: bioactivity of inhaled calcitonin approximates injected calcitonin, J. Bone Min. Res., 11, S95, 1996.
62. Nomura, M., Okuno, T., Yanagawa, A., and Kono, T., Studies on intranasal absorption of new formulation of 1-34 PTH in healthy volunteers, Osteoporosis Int., 6, 269, 1996.
63. Patton, J. S., Trinchero, P., and Platz, R. M., Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones, J. Controlled Release, 28, 79, 1994.
64. Hodsman, A. B., Fraher, L., and Adachi, J. A., Clinical trial of cyclical clodronate as maintenance therapy following withdrawal of parathyroid hormone, in the treatment of post-menopausal osteoporosis, J. Bone Min. Res., 10, kS200, 1995.
65. Sone, T., Fukunaga, M., Ono, S., and Nishiyama, T. A., A small dose of human parathyroid hormone (1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis, Min. Electrol. Metab., 21, 232, 1995.
66. Pak, C. Y. C., Sakhaee, K., Piziak, V., Peterson, R. D., Breslau, N. A., Boyd, P., Poindexter, J. R., Herzog, J., Heard-Sakhaee, A., Haynes, S., Adams-Huet, B., and Reisch, J. S., Slow-release sodium fluoride in the management of postmenopausal osteoporosis, Ann. Int. Med., 120, 625, 1994.
67. Adami, S., Baroni, M. C., Broggini, M., Carratelli, L., Caruso, I., Gnessi, L., Laurenzi, M., Lombardi, A., Norbiato, G., and Ortolani, S., Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin, Osteoporosis Int., 3, S21, 1993.